Meet us in Salt Lake City!There's still time to register to join us on November 4th in Salt Lake City for an in-person patient education conference. You can view the agenda and the program booklet here. We've gathered some of the best NET experts to answer your questions and present information about research and clinical trials, what's new in NETs, symptom management, and more.
| |
NET Cancer Day is November 10th
NETRF will launch a 10-day social media campaign from November 1 through November 10th to support the goal of raising awareness, improving the quality of life for NET patients, and the importance of funding research to develop treatments and eventual cures for neuroendocrine cancer.
We need the help of our global community to accomplish these critical objectives! So please mark your calendars to like and share our social posts November 1-10. Thank you!
| |
Support NETRF When You Shop Online!
We’re sharing a great new program, developed by NETRF Board of Directors member Steve Kaufer, called Give Freely, which acts as a shopping assistant and automatically finds discount coupons whenever you shop online.
The amazing twist? Whenever you buy anything at over 10,000 partner sites, a portion of the purchase price will go to NETRF. It’s free to use and costs you absolutely nothing. Behind the scenes, the store is paying Give Freely a commission on the purchase, and 100% of that commission is donated to NETRF. No credit card. No annoying popups. Save money, support NETRF, and make a difference, all while doing your regular online shopping.
What's more? For the next six months, Steve will donate $10 for each person who installs Give Freely and selects NETRF as their charity of choice.
You can learn more and install Give Freely into your browser from the Give Freely Website. And don’t worry, we trust it: it is safe, secure, and doesn’t ask for a credit card.
| |
 |
NETRF CEO Elyse Gellerman and Chief Development Officer Susan Harrington pictured with Jim Jungsten
|
|
"Sheryl Strong" Benefit for NETRF
Oh What A Night! On Friday, October 20th in Fair Oaks California, Jim Jungsten's community showed up for Sheryl. Proceeds from the online auction and the evening's live auction will benefit NETRF and our unwavering commitment to fund researchers dedicated to finding treatments and cures for NETs.
We are so grateful to Jim and congratulate him on his proclamation from Sacramento County Supervisor Rich Desmond for his tireless commitment to raise awareness of neuroendocrine cancer and NETRF in memory of his fiancé, Sheryl.
| |
Mark Your Calendar to DOUBLE Your NETRF Impact
On November 28, 2023, NETRF will mark Giving Tuesday, an annual global generosity movement. This year, inspired by the spirit of Giving Tuesday, our Board of Directors, led by Dr. Laurie Littlepage, Suzanne Ludlow, and Tony Detre, have pledged to match each donation - up to $45,000 - to help us reach a special goal: funding a NETRF Pilot Award. These one-year, $90,000 grants provide vital seed funding for investigators to kickstart novel approaches to research and help rising stars stay in the field. Stay tuned for more Giving Tuesday details about how you can double your impact and drive NET discoveries around the world.
| |
NET Thrivership: Sharing Your Story
For this month’s Thrivership Series we are sharing United States Congressman Joaquin Castro's (TX) NET story. The Congressman joined the NET community in Austin, Texas at NETRF's NET Impact Program on September 23rd and shared, for the first time publicly, his personal NET story. Watch Rep. Castro’s talk here.
Sharing your NET story can be helpful for several reasons. Sharing your experience can connect you with others who have gone through similar challenges, providing a sense of community and emotional support. Your story can raise awareness about NETs, its impact, the importance of early detection and prevention, and your NET journey can inspire and motivate others facing NETs. By openly discussing NETs, you contribute to reducing the stigma associated with the disease, making it easier for others to seek help and share their experiences. Sharing your NET story can be a therapeutic way to cope with your own emotions and promote personal healing. Do you have a NET journey you would like to share? Please e-mail us at info@netrf.org.
| |
NETWise Episode 29: Merkel Cell Carcinoma
Merkel Cell Carcinoma has recently been covered in the news as entertainer Jimmy Buffet's cause of death.
Merkel Cell Carcinoma can be challenging to diagnose and treat, making early detection and medical attention crucial. This NETWise episode focuses on Merkel Cell Carcinoma with experts from Dana-Farber Cancer Institute and the University of Washington. After you listen, test your knowledge by taking the LACNETS NET quiz here.
| |
Test Your Knowledge!
After you've listened to the NETWise Merkel Cell Carcinoma episode, test your knowledge by taking the LACNETS quiz here.
| |
|
Response Criteria and PRRT Treatment
Through her 2021 NETRF Investigator Award, Lisa Bodei, MD, PhD, professor of radiology at Weill Cornell Medical College, attending physician and director of targeted radionuclide therapy, molecular imaging and therapy service at Memorial Sloan Kettering Cancer Center, is defining how to use PET scans to evaluate a patient’s response to treatment such as peptide receptor radionuclide therapy (PRRT). PET is an incredibly accurate technology to stage neuroendocrine tumors and select patients for PRRT, but it’s not yet clear how to use PET to monitor treatment response. Read more here.
| |
Positive Results in NETTER II Trial
Positive results from the Phase III NETTER-2 trial were reported in September. The NETTER-2 trial is a randomized, multi-center trial evaluating whether Lutathera® plus long-acting octreotide when taken as a first line treatment can prolong progression-free survival in patients with Grade 2 and 3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs) when compared to treatment with high-dose, long-acting octreotide alone. The trial met its primary endpoint finding statistically significant and clinically meaningful progression-free survival in first line treatment with Lutathera® in combination with long-acting octreotide. Read more here.
| |
|
|
|
|
